Please assess the completion status of the following clinical trial:

Trial Title: A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women and Men between 18 and 80 years of age inclusive~* Have refractory chronic cough~* Women of child-bearing potential must use 2 forms of acceptable birth control - Have provided written informed consent.~* Are willing and able to comply with all aspects of the protocol~Exclusion Criteria:~* Current smoker~* Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio \<60%~* History of upper or lower respiratory tract infection or recent significant change in pulmonary status within 4 weeks of the Baseline Visit~* History of opioid use within 1 week of the Baseline Visit~* Body mass index (BMI) \<18 kg/m\^2 or ≥ 40 kg/m\^2~* History of concurrent malignancy or recurrence of malignancy within 2 years prior to Screening (not including subjects with \<3 excised basal cell carcinomas)~* Screening systolic blood pressure (SBP) \>160 mm Hg or a diastolic blood pressure (DBP) \>90 mm Hg~* Clinically significant abnormal electrocardiogram (ECG) at Screening~* Significantly abnormal laboratory tests at Screening~* Pregnant or Breastfeeding~* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the Investigator or Sponsor, would make the participant inappropriate for entry into this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received one matching placebo tablet administered by mouth twice daily for 12 weeks.
- Gefapixant 7.5 mg (Type: EXPERIMENTAL): Participants received one 7.5 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
- Gefapixant 20 mg (Type: EXPERIMENTAL): Participants received one 20 mg gefapixant tablet administered by mouth twice daily for 12 weeks.
- Gefapixant 50 mg (Type: EXPERIMENTAL): Participants received one 50 mg gefapixant tablet administered by mouth twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).